Given the association with PD-L1 expression, our findings support the potential for combination immunotherapy with MET, KRAS inhibitors, and CD274/PDCD1LG2 amplification, which may support eligibility for treatment with anti-PD-1/PD-L1 agents for patients with NSCLC. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.